ABCB1 Polymorphism Testing for Antidepressant CNS Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressants have unsatisfactory clinical efficacy due to inadequate penetration into the central nervous system, largely due to the blood-brain barrier's active transport mechanisms, and there is a need to identify polymorphisms in the ABCB1 gene that predict treatment outcomes for CNS-active medications.
Innovation Solution
Identification of new single nucleotide polymorphisms in the ABCB1 gene, specifically rs4148740, rs10280101, rs7787082, rs4148739, rs11983225, rs10248420, and rs12720067, which are associated with the clinical response to CNS-active medications, allowing for personalized treatment approaches by determining polymorphisms in patients to predict treatment outcomes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antidepressants are administered to treat major depression, then clinical treatment is provided, but clinical efficacy is insufficient due to inadequate penetration into the central nervous system
Solution Approach 1:
The patent applies preliminary action by determining ABCB1 polymorphisms before administering antidepressants. This pre-treatment genetic testing allows clinicians to predict whether a patient will have adequate drug penetration into the CNS, enabling selection of appropriate medications or dosage adjustments before treatment begins, thereby avoiding the problem of insufficient clinical efficacy that occurs with standard empiric prescribing
Solution Approach 2:
The patent applies parameter changes by using genetic polymorphism information to adjust treatment parameters. Specifically, the presence of certain ABCB1 polymorphisms (such as 2677G>T/A) indicates reduced P-gp function, which allows for lower dosages of antidepressants or selection of drugs with better CNS penetration, thereby optimizing clinical efficacy while accounting for individual variations in drug transport across the blood-brain barrier
2Productivity
If standard dosing is used for antidepressants, then treatment simplicity is maintained, but remission rates are low occurring in only about half of patients
Solution Approach 1:
The patent implements preliminary genetic testing for ABCB1 polymorphisms before initiating antidepressant treatment. This pre-assessment allows clinicians to identify patients with genetic variants associated with poor response (such as 2677G>T/A carriers) and adjust their treatment plans accordingly, thereby increasing remission rates from the current ~50% to potentially higher rates by avoiding ineffective standard dosing in genetically susceptible individuals
Solution Approach 2:
The patent introduces genetic testing as an intermediary step between diagnosis and treatment selection. This intermediary assessment of ABCB1 polymorphisms provides critical information that mediates the decision-making process, allowing clinicians to select appropriate antidepressants or dosages based on predicted CNS penetration, thereby improving remission rates without requiring complex treatment protocols
3Measurement precision
If ABCB1 polymorphisms are determined to predict treatment outcomes, then personalized treatment can be implemented, but diagnostic complexity increases
Solution Approach 1:
The patent applies local quality by focusing genetic testing on specific, clinically relevant ABCB1 polymorphisms (such as 2677G>T/A) rather than performing comprehensive genomic analysis. This targeted approach to testing only the most important genetic variants associated with P-gp function and antidepressant response provides accurate treatment outcome prediction while minimizing diagnostic complexity and cost
Solution Approach 2:
The patent simplifies the diagnostic process by reducing the number of genetic parameters tested to only those with proven clinical significance for antidepressant response. By focusing on specific ABCB1 polymorphisms known to affect P-gp function and CNS drug penetration, the patent achieves high measurement precision for treatment outcome prediction without requiring complex multi-parameter genetic profiling
Data Source
AI summary
The present invention relates to methods, compositions, kits and reagents for determining the prognosis of a clinical response in a human patient to a medicament which acts in the central nervous system (CNS) and which is a substrate of the ABCB1 protein. Further, the invention relates to a combination of medicaments for the treatment of human patients having specific polymorphisms in the ABCB1 gene.